New WHO statement on public reporting of clinical trial results announced

The World Health Organization (WHO) have announced a new statement on the public disclosure of clinical trial results which updates and expands a previous statement that noted the "the registration of all interventional trials is a scientific, ethical, and moral responsibility." The new statement includes timelines by which researchers are expected to report clinical trials results. In an Essay published in this week's PLOS Medicine Vasee Moorthy and colleagues from the WHO outline the rationale behind the new statement.

A new element in the WHO statement is the definition of timelines for researchers to report the main findings of clinical trial results: by posting to the results section of the primary clinical trial registry within 12 months of study completion, and by publishing within a peer-reviewed journal within 24 months of study completion.

The authors conclude, "WHO calls for ethics committees, regulatory authorities, professional bodies, sponsors, investigators, and funding agencies to act in their jurisdictions to ensure results from all interventional clinical trials are reported and publicly disclosed."

In an accompanying Perspective article, also published in PLOS Medicine, Ben Goldacre, from the Centre for Evidence-Based Medicine, Oxford University and co-founder of the AllTrials campaign, hails the announcement as a "landmark position statement" but cautions that "delivering definitive change... will require more than positive statements and good intentions."

In his article Dr Goldacre sets out practical suggestions around audit and accountability to help ensure appropriate reporting of trial results.

Dr Goldacre notes, "[the statement] represents important progress on a long-standing and global structural problem that has a clear, negative impact on patient care. The best currently available evidence shows that the methods and results of clinical trials are routinely withheld from doctors, researchers, and patients... undermining our best efforts at informed decision making. From this point forward, whenever the methods and results of a trial are withheld, doctors, patients, researchers, campaigners, and health care providers will be able to point at an unambiguous statement from WHO."

Moorthy VS, Karam G, Vannice KS, Kieny M-P (2015) Rationale for WHO's New Position Calling for Prompt Reporting and Public Disclosure of Interventional Clinical Trial Results. PLoS Med 12(4): e1001819. doi:10.1371/journal.pmed.1001819

Most Popular Now

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

WHO grants prequalification to GSK's Mosquirix - t…

GSK plc (LSE/NYSE: GSK) announced that the World Health Organization (WHO) has awarded prequalification to Mosquirix (also known as RTS,S/AS01), GSK's groundbreaking mala...

Bird's enzyme points toward novel therapies

Thank the rare crested ibis for a clue that could someday help our bodies make better drugs. The species of bird is the only one known to naturally produce an enzyme ...

WHO strongly advises against antibody treatments f…

The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with COVID-19, says a WHO Guideline Development Group of international experts in...